AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02711319 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
Study NCT01115686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain aminoacids
Description: Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks.
Study NCT01115686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks.
Study NCT04775147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering
Description: The aim is to achieve a systolic BP level of \<120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)
Study NCT03089996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
Study NCT03089996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
Study NCT03089996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Side
Description: The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
Study NCT03089996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations
Description: All micro-osteoperforations will be performed only once time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations will be performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations will be controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations will be aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation will be performed between the two central incisors. The first perforation will be performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
Study NCT03052348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Description: Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
Study NCT03052348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
Description: Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
Study NCT02290925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kothala Himbutu Biscuit
Description: Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
Study NCT02290925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Biscuit
Description: Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
Study NCT01614353 — intervention group
Intervention type: OTHER
Intervention: Electronic Diaries
Description: Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
Study NCT01614353 — intervention group
Intervention type: OTHER
Intervention: Hermeneutic Interviews
Description: Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
Study NCT01107899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: taken orally, day one, single dose
Study NCT01107899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: taken orally, day one, single dose
Study NCT01107899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: taken orally, day one, single dose
Study NCT01726569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: film and trained counseling
Description: Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
Study NCT01726569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional counseling
Description: Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
Study NCT01726569 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional counseling
Description: Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
Study NCT03020953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + Estrogen
Description: 12 weeks resistance training and estrogen patches
Study NCT03020953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise + Placebo
Description: 12 weeks resistance training and placebo patches
Study NCT02531867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asfotase Alfa
Study NCT00902798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
Study NCT00902798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
Study NCT05747612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Coaching
Description: Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives.
Study NCT03985436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trek for Surgical Success
Description: Cognitive behavioral therapy for pain
Study NCT00273286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family diabetes management intervention
Description: a clinic-integrated, low intensity, multi-component behavioral intervention
Study NCT04303507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or Hydroxychloroquine
Description: A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
Study NCT04303507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02112890 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
Study NCT00564148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
Study NCT04259359 — intervention group
Intervention type: DRUG
Intervention: Insect Venom
Description: Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
Study NCT00701909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus Ketamine
Description: Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV
Study NCT00701909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine plus Ketamine
Description: Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV
Study NCT00701909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus Saline (placebo)
Description: Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.
Study NCT00701909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine plus Saline (placebo)
Description: Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.
Study NCT02472002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal cell therapy
Description: Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~* Registry Type: autologous~* Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~* Route of administration: endomyocardial injection~* Dose administered: 120-140 x106 MSC (mesenchymal stem cells)
Study NCT02836288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
Study NCT02836288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo syrup will be given by mouth once a day for 12 weeks.
Study NCT02836288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo syrup will be given by mouth once a day for 12 weeks.
Study NCT02539849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FOS
Study NCT02539849 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Study NCT02551211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood drawn
Description: blood drawn
Study NCT02551211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection of cancer
Study NCT01118559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT01142167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard colonoscopy will be used during colonoscopy
Study NCT01142167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra-thin colonoscopy
Description: Ultra-thin colonoscope will be used during colonoscopy
Study NCT02147847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based training 1
Description: 32 one-hour, home-based training sessions over 8 weeks
Study NCT02147847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based training 2
Description: 32 one-hour, home-based training sessions over 8 weeks
Study NCT01561482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
Study NCT01561482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
Study NCT04183998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans-spinal Electrical Stimulation (tsES)
Description: Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
Study NCT00910897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade-Dexamethasone
Study NCT00910897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade-Thalidomide-Dexamethasone
Study NCT03037047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
Study NCT03037047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolate injection
Description: Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
Study NCT01458522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fPHT
Description: If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
Study NCT01458522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fPHT
Description: If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
Study NCT01458522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCM
Description: If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
Study NCT01458522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCM
Description: If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments.
Study NCT00516139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Open-label
Study NCT00466609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomipramine (fluoxetine plus clomipramine)
Description: Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
Study NCT00466609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine (fluoxetine plus quetiapine)
Description: Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
Study NCT00466609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fluoxetine plus placebo)
Description: Placebo plus fluoxetine at maximum dosage of 80mg per day